French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation ...
French pharmaceutical company Sanofi announced Tuesday a partnership with ChatGPT-founder OpenAI and US biotech firm Formation Bio to accelerate the use of artificial intelligence in developing drugs.
Sanofi SA (EPA: SAN) is in focus today after teaming up with OpenAI to deploy artificial intelligence for drug development.
Sanofi CEO Paul Hudson thinks AI offers 'insane' potential for the pharmaceutical industry, which can spend up to $4 billion developing a drug.
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, . Sanofi, Formation Bio and OpenAI are collaborating to ...
Sanofi will offer its extensive data under the deal to develop solutions for drug development. Credit: HJBC / ...
French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug ...
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new ...
(Reuters) - French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of ...
Sanofi said in a statement that the partnership with OpenAi will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional ...